Journal
MOLECULAR THERAPY
Volume 18, Issue 1, Pages 118-125Publisher
CELL PRESS
DOI: 10.1038/mt.2009.246
Keywords
-
Categories
Funding
- Kettering Family Foundation [P01-HD057247, P01-HL059407, P30-DK047757]
- GlaxoSmithKline
- China Scholarship Council
- EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P01HD057247] Funding Source: NIH RePORTER
- NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL059407] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK047757] Funding Source: NIH RePORTER
Ask authors/readers for more resources
Vectors based on adeno-associated viruses (AAVs) are being evaluated for use in liver-directed gene therapy. Candidates have been preselected on the basis of capsid structure that plays an important role in determining performance profiles. We describe a comprehensive and statistically powered set of mouse studies designed to compare the performance of vectors based on seven novel AAV capsids. The key criteria used to select candidates for successful gene therapy are high level and stable transgene expression in the absence of toxicity. Based on these criteria, the best performing vectors, AAV8, AAVhu. 37, and AAVrh. 8, will be further evaluated in nonhuman primates (NHPs).
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
